聚乙二醇化干扰素α-2b单药治疗及聚乙二醇化干扰素α-2b联合拉米夫定治疗乙肝病毒e抗原阴性慢性乙型肝炎患者
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
作者信息
Kaymakoglu Sabahattin, Oguz Dilek, Gur Gurden, Gurel Selim, Tankurt Ethem, Ersöz Galip, Ozenirler Seren, Kalayci Cem, Poturoglu Sule, Cakaloglu Yilmaz, Okten Atilla
机构信息
Istanbul University, Department of Gastroenterohepatology, Istanbul Medical Faculty, Capa, Istanbul, Turkey.
出版信息
Antimicrob Agents Chemother. 2007 Aug;51(8):3020-2. doi: 10.1128/AAC.00088-07. Epub 2007 May 21.
Abstract
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
摘要
48例乙型肝炎病毒（HBV）e抗原阴性的慢性乙型肝炎患者接受聚乙二醇化干扰素α-2b单药治疗或联合拉米夫定治疗48周，并随访额外24周。随访结束时，单药治疗组（24%）和联合治疗组（26%）的病毒学应答率（HBV DNA水平<400拷贝/ml）相似。
相似文献
1
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
Antimicrob Agents Chemother. 2007 Aug;51(8):3020-2. doi: 10.1128/AAC.00088-07. Epub 2007 May 21.
2
Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
J Gastroenterol Hepatol. 2007 Oct;22(10):1582-8. doi: 10.1111/j.1440-1746.2007.05103.x. Epub 2007 Aug 7.
3
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet. 2005;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0.
4
Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
Med Sci Monit. 2009 Feb;15(2):CR56-61.
5
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
6
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. 2004 Sep 16;351(12):1206-17. doi: 10.1056/NEJMoa040431.
7
8
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Am J Gastroenterol. 2007 Dec;102(12):2718-23. doi: 10.1111/j.1572-0241.2007.01449.x. Epub 2007 Jul 27.
9
Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B.
Scand J Gastroenterol. 2009;44(8):1021-2. doi: 10.1080/00365520902937370.
10
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.
引用本文的文献
1
Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy.
Pediatr Infect Dis J. 2025 Feb 1;44(2):112-117. doi: 10.1097/INF.0000000000004567. Epub 2024 Oct 1.
2
Systematic review and meta-analysis: combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B.
Front Pharmacol. 2024 Jul 5;15:1403805. doi: 10.3389/fphar.2024.1403805. eCollection 2024.
3
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Syst Rev. 2019 Aug 19;8(1):207. doi: 10.1186/s13643-019-1126-1.
4
Alpha-interferon treatment in hepatitis B.
Ann Transl Med. 2017 Apr;5(7):159. doi: 10.21037/atm.2017.03.69.
5
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.
Int J Environ Res Public Health. 2016 Jul 21;13(5):730. doi: 10.3390/ijerph13070730.
6
Interferon and nucleoside analog combination therapy for hepatitis B.
Clin J Gastroenterol. 2010 Apr;3(2):69-72. doi: 10.1007/s12328-010-0135-3. Epub 2010 Feb 23.
7
Economic evaluation of treatments for chronic hepatitis B.
Braz J Infect Dis. 2013 Jul-Aug;17(4):418-26. doi: 10.1016/j.bjid.2012.12.005. Epub 2013 Jul 10.
8
Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
BMC Infect Dis. 2011 Jun 9;11:165. doi: 10.1186/1471-2334-11-165.
9
Combination treatment in HBeAg-negative chronic hepatitis B.
World J Hepatol. 2009 Oct 31;1(1):43-7. doi: 10.4254/wjh.v1.i1.43.
10
Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop.
Hepatol Int. 2008 May;2(Supplement 1):19-27. doi: 10.1007/s12072-008-9059-0. Epub 2008 Mar 5.
本文引用的文献
1
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
Neth J Med. 2006 Jun;64(6):175-85.
2
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.
J Hepatol. 2006 Sep;45(3):355-60. doi: 10.1016/j.jhep.2006.03.007. Epub 2006 Apr 18.
3
The current status of antiviral therapy of chronic hepatitis B.
J Clin Virol. 2005 Dec;34 Suppl 1:S115-24. doi: 10.1016/s1386-6532(05)80020-4.
4
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
5
Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.
J Viral Hepat. 2005 May;12(3):262-8. doi: 10.1111/j.1365-2893.2005.00566.x.
6
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
Ann Intern Med. 2005 Feb 15;142(4):240-50. doi: 10.7326/0003-4819-142-4-200502150-00006.
7
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet. 2005;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0.
8
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. 2004 Sep 16;351(12):1206-17. doi: 10.1056/NEJMoa040431.
9
Treatment of chronic hepatitis B: current challenges and future directions.
Rev Med Virol. 2003 Jul-Aug;13(4):255-72. doi: 10.1002/rmv.393.
10
Current state of interferon therapy in the treatment of chronic hepatitis B.
Semin Liver Dis. 2002;22 Suppl 1:7-13. doi: 10.1055/s-2002-35695.
Zotero 插件